Systemic juvenile idiopathic arthritis in French Afro-Caribbean children, a retrospective cohort study.
Afro-Caribbean children
Macrophage activation syndrome
Still disease
Systemic juvenile idiopathic arthritis
Journal
Pediatric rheumatology online journal
ISSN: 1546-0096
Titre abrégé: Pediatr Rheumatol Online J
Pays: England
ID NLM: 101248897
Informations de publication
Date de publication:
16 Nov 2022
16 Nov 2022
Historique:
received:
15
09
2022
accepted:
04
11
2022
entrez:
17
11
2022
pubmed:
18
11
2022
medline:
22
11
2022
Statut:
epublish
Résumé
The epidemiology and clinical presentation of systemic juvenile idiopathic arthritis (sJIA) in the Afro-Caribbean population is not well described. Retrospective study conducted between January 2000 and January 2022 in the French Overseas Departments of America. Clinical data were obtained from multiple sources: computerized hospital archives, registries of referring pediatricians, and the French National Registry for rare diseases. The disease studied was sJIA defined according to international criteria. Twenty-five patients were identified. Mean age at diagnosis was 7.5 years (range: 1.2-14.9 years) and mean duration of follow-up was 5.2 years (range: 0.5-16 years). All patients had joint involvement at diagnosis with 68% presenting inflammatory arthritis and 32% inflammatory joint pain. Sixteen percent had coronary involvement at onset. More than half (52%) suffered from macrophage activation syndrome (MAS) during childhood (32% at onset). The mean number of flares in childhood was 2 (Range: 1-5). Sixty-eight percent of patients had disease control during childhood without biotherapy. The most frequent second line treatment was anakinra (7/8). There was no difference in clinical or biological severity according to gender. The median duration of treatment during childhood was 5 months (range: 2-144) and 72% had a cumulative treatment duration of less than one year. These patients of Afro-Caribbean origin suffering from sJIA showed some specificities, such as a higher rate of MAS and coronary involvement at onset. The incidence per year was stable over a 20-year period. Overall outcomes during childhood were similar to western countries.
Identifiants
pubmed: 36384585
doi: 10.1186/s12969-022-00766-8
pii: 10.1186/s12969-022-00766-8
pmc: PMC9668386
doi:
Substances chimiques
Interleukin 1 Receptor Antagonist Protein
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
98Informations de copyright
© 2022. The Author(s).
Références
J Rheumatol. 2004 Feb;31(2):390-2
pubmed: 14760812
Arthritis Res Ther. 2009;11(3):229
pubmed: 19519924
J Rheumatol. 2019 Feb;46(2):190-197
pubmed: 30275259
Ann Rheum Dis. 2022 Jul;81(7):990-997
pubmed: 35260388
Joint Bone Spine. 2014 May;81(3):257-9
pubmed: 24793086
Lancet. 2007 Oct 20;370(9596):1453-7
pubmed: 18064739
Pediatr Rheumatol Online J. 2017 Jan 31;15(1):7
pubmed: 28143550
Pediatr Clin North Am. 2018 Aug;65(4):691-709
pubmed: 30031494
Immunol Med. 2021 Dec;44(4):237-245
pubmed: 33982649
Arthritis Rheumatol. 2016 Mar;68(3):566-76
pubmed: 26314788
Lancet. 2011 Jun 18;377(9783):2138-49
pubmed: 21684384
J Rheumatol. 2007 May;34(5):1133-8
pubmed: 17343315
Pediatr Rheumatol Online J. 2013 Sep 14;11(1):33
pubmed: 24034206
Autoimmun Rev. 2011 Jun;10(8):482-9
pubmed: 21320644
Pediatr Rheumatol Online J. 2016 Apr 27;14(1):27
pubmed: 27121190